Cyclopharm Director Increases Shareholding via Share Purchase Plan

Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.

Cyclopharm has disclosed a change in the shareholding of director John William Wigglesworth, who increased his direct holding in the company through participation in a share purchase plan. He acquired 21,052 ordinary shares for a total consideration of $19,999.40 on 12 March 2026, lifting his stake from 67,479 to 88,531 shares, with the trade confirmed as occurring outside any closed trading period.

The transaction, conducted under the company’s share purchase plan rather than via on-market trading, signals continued insider support for Cyclopharm’s equity raising mechanism and capital management activities. For investors, the enlarged director holding may be interpreted as an expression of confidence in the company’s prospects and governance, although no additional contractual interests or changes in derivative positions were reported.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian-listed company, identified by ABN 74 116 931 250, operating in the healthcare sector and focused on medical technologies, including nuclear medicine products. The company’s shares are traded on the ASX, and its governance disclosures include regular reporting of directors’ dealings in its ordinary shares.

Average Trading Volume: 89,869

Technical Sentiment Signal: Sell

Current Market Cap: A$88.05M

See more insights into CYC stock on TipRanks’ Stock Analysis page.